Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

MOTS-c and Studies in Insulin & Inflammation - Biotech Peptides

MOTS-c Peptide and Studies in Insulin & Inflammation by Dr. Usman | Feb 7, 2023 | Research Contents: MOTS-c Peptide Research in Insulin Resistance, Metabolism, and Muscle MOTS-c Peptide and the Heart MOTS-c Peptide and Bone References Featured Product MOTS-c P

By Recovery & Performance Peptides Editorial Team

MOTS-c Peptide and Studies in Insulin & Inflammation

by Dr. Usman | Feb 7, 2023 | Research

Contents:

MOTS-c Peptide Research in Insulin Resistance, Metabolism, and Muscle

MOTS-c Peptide and the Heart

MOTS-c Peptide and Bone

References

Featured Product

MOTS-c Peptide Overview

MOTS-c is a naturally produced component of mitochondria, the cellular organelles responsible for producing energy. The structure of the peptide consists of 16 amino acids and bears the sequence H-Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg-OH.

Preliminary research investigates its potential spectrum of action.[1] The studies report, “Under stress conditions, MOTS-c translocates to the nucleus where it regulates a wide range of genes in response to metabolic dysfunction.” Thus, MOTS-c is thought to regulate energy metabolism and may have anti-inflammatory and anti-cell aging characteristics.

MOTS-c Research in Insulin Resistance, Metabolism, and Muscle

One of the most actively researched potentials of MOTS-c is its action on insulin resistance and metabolic function. Several animal studies suggest MOTS-c may help improve glucose metabolism in metabolic disorders such as insulin resistance by targeting skeletal muscles.[2] This mechanism of action may work by enhancing glucose uptake by skeletal muscles and may also helps decrease levels of visceral fat.

One of these studies reports that MOTS-c targets the skeletal muscle and inhibits the folate cycle and its tethered de novo purine biosynthesis, leading to AMPK pathway activation.[3] As a result, MOTS-c exposure in mice appeared to mitigate age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity.

MOTS-c may also help improve metabolic function by stimulating the “browning” of white (beige) fat and increasing thermogenesis in fat tissue.[4] These potential actions of MOTS-c are believed to be mediated by the activation of the ERK signaling pathway.

MOTS-c has also shown promise in studies in gestational diabetes, a type of diabetes that occurs due to increased insulin resistance in pregnancy.[5] In a GDM mouse model, daily exposure to MOTS-c during pregnancy appeared to significantly reduce hyperglycemia, improve insulin sensitivity and glucose tolerance, and reduce birth weight and risk of offspring death.

The action of MOTS-c on skeletal muscles do not appear to be limited to improving their glucose uptake. Animal research also suggests that the peptide has the potential to impact muscle atrophy in obesity and type 2 diabetes.[6] MOTS-c appears to function by decreasing myostatin levels in plasma in mice and elevating AKT phosphorylation, which inhibits the activity of FOXO1, a transcription factor for muscle-wasting genes. It may also potentially reduce dystrophic muscle atrophy, specifically in Duchenne Muscular Dystrophy (DMD) models.[7]

MOTS-c Peptide and the Heart

MOTS-c peptides may exert a protective action on the heart muscle due to improved mitochondria function in the myocytes. According to one study in a murine model of heart failure, the peptide appeared to reduce the inflammation response and improve cardiac function.[8] The peptide also appeared to activate the AMPK pathway, reduce cell apoptosis, and improve the antioxidant capacity in the heart of the mice.

MOTS-c may also help reduce certain adverse actions of type 2 diabetes on the heart, as studies in diabetic rats suggested that peptide exposure appeared to result in improved myocardial mitochondrial damage, preserve cardiac systolic and diastolic function, and altered 47 disease-causing genes related to apoptosis, immunoregulation, angiogenesis, and fatty acid metabolism.[9]

Thanks to the activation of the AMPK and the anti-oxidative potential of the peptide, animal studies also suggest it may help reduce inflammation in the heart and protect against vascular calcification (VC), which is a complication of atherosclerosis.[10][11]

Researchers report that MOTS-c may also improve mechanical heart efficiency, enhance heart systolic function, and show a tendency to improve diastolic function in mice.[12] These results suggest that MOTS-c might help to optimize the cardiovascular function. Scientists also suggest that MOTS-c may have heart function action similar to physical stimulation via activating the NRG1-ErbB4-C/EBPβ pathway.[13]

MOTS-c Peptide and Bone

By activating the phosphorylated AMPK, MOTS-c may provide positive impacts on bones. One study reports that in a murine model of osteoporosis, MOTS-c exposure appeared to inhibit osteoclast differentiation and reduce bone loss, as determined by micro-CT examination.[14] The scientists concluded that “MOTS-c may exert as an inhibitor of osteoporosis via AMPK dependent inhibition of osteoclastogenesis.“

Another animal study reported reduced bone erosion and inflammation in a model of osteolysis induced by ultra-high molecular weight polyethylene particles.[15] MOTS-c appeared to increase the osteoprotegerin ratio to receptor activator of nuclear factor kappa-B ligand in osteocytes, inhibiting osteoclastogenesis.

Some laboratory experiments suggest that MOTS-c may promote bone fracture healing by inducing bone marrow stem cell (BMSCs) differentiation into osteoblasts.[16] This may be achieved by increasing the relative levels of bone markers (ALP, Bglap, and Runx2) and activating the TGF-β pathway by the FOXF1 protein to ultimately stimulate the mineralization ability in BMSCs.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

References

Ming W, Lu G, Xin S, Huanyu L, Yinghao J, Xiaoying L, Chengming X, Banjun R, Li W, Zifan L. Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation. Biochem Biophys Res Commun. 2016 Aug 5;476(4):412-419. doi: 10.1016/j.bbrc.2016.05.135. Epub 2016 May 26. PMID: 27237975.

Lee C, Kim KH, Cohen P. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radic Biol Med. 2016 Nov;100:182-187. doi: 10.1016/j.freeradbiomed.2016.05.015. Epub 2016 May 20. PMID: 27216708; PMCID: PMC5116416.

Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015 Mar 3;21(3):443-54. doi: 10.1016/j.cmet.2015.02.009. PMID: 25738459; PMCID: PMC4350682.

Lu H, Tang S, Xue C, Liu Y, Wang J, Zhang W, Luo W, Chen J. Mitochondrial-Derived Peptide MOTS-c Increases Adipose Thermogenic Activation to Promote Cold Adaptation. Int J Mol Sci. 2019 May 17;20(10):2456. doi: 10.3390/ijms20102456. PMID: 31109005; PMCID: PMC6567243.

Yin Y, Pan Y, He J, Zhong H, Wu Y, Ji C, Liu L, Cui X. The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus. Pharmacol Res. 2022 Jan;175:105987. doi: 10.1016/j.phrs.2021.105987. Epub 2021 Nov 17. PMID: 34798268.

Kumagai H, Coelho AR, Wan J, Mehta HH, Yen K, Huang A, Zempo H, Fuku N, Maeda S, Oliveira PJ, Cohen P, Kim SJ. MOTS-c reduces myostatin and muscle atrophy signaling. Am J Physiol Endocrinol Metab. 2021 Apr 1;320(4):E680-E690. doi: 10.1152/ajpendo.00275.2020. Epub 2021 Feb 8. PMID: 33554779; PMCID: PMC8238132.

Ran N, Lin C, Leng L, Han G, Geng M, Wu Y, Bittner S, Moulton HM, Yin H. MOTS-c promotes phosphorodiamidate morpholino oligomer uptake and efficacy in dystrophic mice. EMBO Mol Med. 2021 Feb 5;13(2):e12993. doi: 10.15252/emmm.202012993. Epub 2020 Dec 18. PMID: 33337582; PMCID: PMC7863382.

Zhong P, Peng J, Hu Y, Zhang J, Shen C. Mitochondrial derived peptide MOTS-c prevents the development of heart failure under pressure overload conditions in mice. J Cell Mol Med. 2022 Nov;26(21):5369-5378. doi: 10.1111/jcmm.17551. Epub 2022 Sep 25. PMID: 36156853; PMCID: PMC9639045.

Wang M, Wang G, Pang X, Ma J, Yuan J, Pan Y, Fu Y, Laher I, Li S. MOTS-c repairs myocardial damage by inhibiting the CCN1/ERK1/2/EGR1 pathway in diabetic rats. Front Nutr. 2023 Jan 4;9:1060684. doi: 10.3389/fnut.2022.1060684. PMID: 36687680; PMCID: PMC9846618.

Shen C, Wang J, Feng M, Peng J, Du X, Chu H, Chen X. The Mitochondrial-Derived Peptide MOTS-c Attenuates Oxidative Stress Injury and the Inflammatory Response of H9c2 Cells Through the Nrf2/ARE and NF-κB Pathways. Cardiovasc Eng Technol. 2022 Oct;13(5):651-661. doi: 10.1007/s13239-021-00589-w. Epub 2021 Dec 2. PMID: 34859377.

Wei M, Gan L, Liu Z, Liu L, Chang JR, Yin DC, Cao HL, Su XL, Smith WW. Mitochondrial-Derived Peptide MOTS-c Attenuates Vascular Calcification and Secondary Myocardial Remodeling via Adenosine Monophosphate-Activated Protein Kinase Signaling Pathway. Cardiorenal Med. 2020;10(1):42-50. doi: 10.1159/000503224. Epub 2019 Nov 6. PMID: 31694019.

Yuan J, Wang M, Pan Y, Liang M, Fu Y, Duan Y, Tang M, Laher I, Li S. The mitochondrial signaling peptide MOTS-c improves myocardial performance during exercise training in rats. Sci Rep. 2021 Oct 11;11(1):20077. doi: 10.1038/s41598-021-99568-3. PMID: 34635713; PMCID: PMC8505603.

Yuan J, Xu B, Ma J, Pang X, Fu Y, Liang M, Wang M, Pan Y, Duan Y, Tang M, Zhu B, Laher I, Li S. MOTS-c and aerobic exercise induce cardiac physiological adaptation via NRG1/ErbB4/CEBPβ modification in rats. Life Sci. 2023 Feb 15;315:121330. doi: 10.1016/j.lfs.2022.121330. Epub 2022 Dec 28. PMID: 36584915.

Yan Z, Zhu S, Wang H, Wang L, Du T, Ye Z, Zhai D, Zhu Z, Tian X, Lu Z, Cao X. MOTS-c inhibits osteolysis in the Mouse Calvaria by affecting osteocyte-osteoclast crosstalk and inhibiting inflammation. Pharmacol Res. 2019 Sep;147:104381. doi: 10.1016/j.phrs.2019.104381. Epub 2019 Jul 29. PMID: 31369811.

Weng FB, Zhu LF, Zhou JX, Shan Y, Tian ZG, Yang LW. MOTS-c accelerates bone fracture healing by stimulating osteogenesis of bone marrow mesenchymal stem cells via positively regulating FOXF1 to activate the TGF-β pathway. Eur Rev Med Pharmacol Sci. 2021 Mar;25(6):2459. doi: 10.26355/eurrev_202103_25396. PMID: 33829422.

Dr. Usman

Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.

Latest Post

BPC157: Molecular Characterization, Pleiotropic Signaling Mechanisms, and Preclinical Research

Copper Peptides: Molecular Characterization, Mechanistic Biology, and Emerging Research

Modified GRF 1-29 and GHRP-2 Peptide Blend: Receptor Pharmacology, Somatotroph Signaling, and Neuroendocrine Research

Fragment 176-191, Modified GRF 1-29, and Ipamorelin Blend: Adipose Metabolism, GH Axis Modulation, and Receptor Signaling Research

PNC-27: Structural Characterization, HDM-2-Dependent Membrane Targeting, and Selective Tumor Cell Necrosis

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

MOTS-C Dosing Protocols for Training Periodisation

Research-grade MOTS-C is typically administered at 5–10mg per injection, 2–3 times weekly, via subcutaneous or intramuscular routes. The half-life is approximately 2–3 hours in circulation, but the metabolic effects persist for 48–72 hours due to sustained AMPK activation and downstream gene expression changes. Athletes structure dosing around training intensity. Administering MOTS-C 30–60 minutes before high-volume WODs or heavy Olympic lifting sessions to maximise glucose availability during the workout window. Periodisation matters. During base-building phases focused on aerobic capacity and movement refinement, MOTS-C pairs well with steady-state conditioning because the AMPK pathway favours fat oxidation when glucose demand is moderate. During competition prep or peaking blocks with multiple daily sessions, athletes increase frequency to 3–4 injections weekly to sustain recovery between sessions. The peptide doesn't interfere with creatine phosphate stores or short-duration power output, so it doesn't blunt performance in 1RM testing or sub-10-second sprints. The benefits emerge in sustained efforts lasting 3–20 minutes where substrate depletion becomes the limiting factor. One critical note: MOTS-C administration timing relative to meals affects absorption and metabolic partitioning. Injecting in a fasted state maximises AMPK activation because insulin and AMPK pathways are reciprocally regulated. High insulin blunts AMPK signalling. Athletes often dose pre-training in…
SIDE EFFECTS

MOTS-c Side Effects and Safety

Since MOTS-c is a relatively new discovery, its safety profile is still being investigated, and further research is needed to fully understand potential side effects. Laboratory animal studies have demonstrated positive outcomes with MOTS-c treatment, showing improvements in metabolic health, physical performance, and age-related decline. However, these studies have primarily focused on the efficacy and therapeutic potential of MOTS-c, rather than extensively examining its safety profile [5, 6]. To establish the safety of MOTS-c, it is crucial to conduct comprehensive toxicology studies in laboratory animals, including dose-response assessments, long-term exposure evaluations, and investigations into potential adverse effects. Limited human studies have been conducted thus far to assess the safety and tolerability of MOTS-c. In a phase 1a/1b clinical trial of the MOTS-c analog CB4211, which was completed in 2021, the results suggested that CB4211 was generally well-tolerated with no serious adverse events reported [10]. However, it is important to note that this trial was conducted with a different analog of MOTS-c, and the findings may not directly apply to MOTS-c itself. As with any investigational compound, it is essential to proceed with caution when considering the use of MOTS-c in humans. Rigorous safety evaluations, including controlled clinical trials, are necessary to assess potential side effects, drug interactions, and long-term effects. Researchers and regulatory…
02

Question drills

Open a question for its connected answer.

01What If I Miss a Scheduled Dose — Should I Double Up?+

No. AMPK phosphorylation peaks 90–120 minutes post-injection and returns to baseline within 24–36 hours. If you miss a Monday dose, administer it Tuesday and continue the regular schedule (Wednesday, Friday). Do not inject twice in one day. Doubling the dose does not extend AMPK activation duration and increases injection site inflammation risk. The three-times-weekly protocol maintains overlapping activation windows; missing one dose reduces cumulative exposure by approximately 15% over a 12-week cycle, which still produces measurable insulin sensitivity improvements based on trial dose-response curves.

SOURCE / realpeptides.co ↗
02What If I'm Using MOTS-C Alongside Metabolic Interventions Like Fasting or Keto?+

MOTS-C's AMPK activation complements both. Fasting and ketogenic diets already trigger AMPK signaling by reducing glucose availability. Adding MOTS-C may amplify metabolic flexibility (the ability to switch efficiently between glucose and fat oxidation). However, this also means more pronounced effects during adaptation phases. If you're within the first two weeks of a dietary shift and experiencing brain fog (common during keto adaptation), MOTS-C may accelerate the transition by improving mitochondrial fat oxidation capacity. The Energy Mitochondria Fatigue Bundle combines MOTS-C with complementary compounds targeting cellular energy pathways for this exact use case.

SOURCE / realpeptides.co ↗
03What if I combine MOTS-c with other recovery peptides like BPC-157?+

No published research examines peptide stacking protocols. MOTS-c and BPC-157 operate through different mechanisms. MOTS-c targets mitochondrial metabolism while BPC-157 influences angiogenesis and tissue repair signaling. Theoretically, they're complementary rather than redundant, but without controlled trials, we can't predict interaction effects or optimal dosing adjustments. Our team's assessment: if you're considering peptide stacking, work with a research context that includes biomarker tracking (CK levels, inflammatory markers, HRV) to measure actual recovery rather than perceived benefit.

SOURCE / realpeptides.co ↗
04What If I've Been Using a Generic MOTS-c Protocol and Not Seeing Results?+

Switch to the MOTS-c 50s age specific protocol immediately. Extend your cycle to 8–10 weeks and reduce your dose to 5mg three times weekly if you were running higher doses at lower frequency. The issue is almost never the peptide's potency; it's that mitochondrial adaptation timelines in aging populations require sustained, consistent receptor activation rather than high-intensity acute dosing. Expect to see measurable changes in fasting glucose or insulin sensitivity within 4–6 weeks once the protocol aligns with your mitochondrial turnover rate.

SOURCE / realpeptides.co ↗
05What If I Want to Study Fat Loss — Which Compound Should I Use?+

Use Tesofensine if the research question involves appetite suppression mechanisms, caloric restriction adherence, or CNS-mediated feeding behavior. It drives fat loss by reducing intake, not by improving oxidative capacity. Use MOTS-c if the question involves metabolic adaptation during caloric deficit, substrate utilization shifts during exercise, or insulin sensitivity changes independent of weight loss. MOTS-c won't create a caloric deficit on its own. It improves how the body responds metabolically to a deficit that already exists through diet or activity.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Research Timeline Considerations

MOTS-C peptide crafte demonstrates different temporal effects compared to other peptides: Immediate effects (1-6 hours): AMPK activation and metabolic shifts Short-term effects (24-72 hours): Gene expression changes Medium-term effects (1-2 weeks): Mitochondrial adaptations Long-term effects (4+ weeks): Systemic metabolic improvements This timeline differs significantly from peptides like CJC-1295 variants which may show different temporal patterns of activity.

RESEARCH

Future Directions in MOTS-C Peptide Research

The field of MOTS-C peptide research continues to evolve rapidly, with exciting developments on the horizon. Current research directions include:

05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles

Regulating Blood Sugar with MOTS-c Peptide

Maintaining steady glucose supports sharp focus, constant energy, and leaner body-composition outcomes in laboratory settings. Among the emerging tools for regulating blood sugar, the mitochondrial peptide MOTS-c has dr…

Read article